chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Within 48 hours of the vaccine, I had a bad episode vertigo. I had nausea, my head was spinning very quickly, and felt very sick.
Temporal fever for one day, blotchy erythematous rash (<24 hours, resolved by follow up next day)
Top of mouth and tongue tingling and full. No meds given. Refused to go to ER
My daughter received the flu vaccine 45 minutes after she received the Bivalent vaccine from another facility.  On our way out of the building, she verbalized that she wanted to cough but can't & started complaining of dyspnea/ shortness of breath, & chest tightness. She was scared, tearful, & didn't want to talk. I didn't not hear any wheezing from her. We walked to the ER, vital signs were stable. It took about 20 minutes before she felt better & I checked her out without being seen by MD. No lingering symptoms were noted the next day except for fever & fatigue.
8th day after vaccination:  woke with itchy, very red, hot, firm, raised rash 3 inches by 1  1/ 2 inches at injection site. Temperature 97.3 degrees (normal temp. is 97.7).    Two days after rash appeared, felt feverish, temp was 98.0.  Nine days after rash appeared, rash was gone. Final rash dimensions 6 1/2" X 4". Experienced some fatigue during the 9 days.
Was administered second dose if Moderna 2 weeks early. Earliest dose would have been on 4/15/21..
Had shot on 5/18/04. Symptoms started within 72 hours. Fever greater than 104 degrees/ chills. Seizure-like activity (jerking of limbs, no loc). Lethargy. Facial rash. Nausea/vomiting/Diarrhea. Mom verbalized reaction to vacc. on the 26th, pt already recovering. She did not bring the pts in for treatment.
pt recv vax 13FEB97 & 12JUN97 pt exp mild case w/a lot of spots;
Presented with acute chest pain that was relieved with leaning forward. Chest pain began acutely the evening of 9/2/2021. Found to have diffuse ST elevation on serial EKGs. Cardiac enzymes negative. Echo performed and was normal. Idiopathic pericarditis diagnosed. Cardiology follow up planned as an outpatient. Started on ibuprofen 600mg po TID and colchicine 0.6mg po q 12 hours. NSAIDs will be tapered. Colchicine planned for at least 3 months. Patient had similar symptom 2 months ago relieved with prednisone 20mg po q day x 3 days.
Circular reddish "rash" in area of vaccine injection. About 3 - 4 inches in diameter.
Patient complained of tachycardia 5min after second dose Pfizer Vaccine, has history of vaccine reactions in past. Sent to ER with Operations lead
Pain at the site of injection for 24 hours, then 4 days later continuous tachycardia (day 5 of elevated heart rate today)
This spontaneous report as received from a doctor of pharmacy refers to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On 24-OCT-2013, the patient was vaccinated with ZOSTAVAX (lot # J000443 and expiry date 11-APR-2014) (dose and route were not reported). No concomitant medication was reported. The call was reported originally on 04-NOV-2013 in which the reporter requested the stability for an improperly stored ZOSTAVAX. At the time of the call it was reported that the ZOSTAVAX was exposed to 15F for an unspecified amount of hours but reported that no doses of ZOSTAVAX were administered. The reporter called back again on 05-NOV-2013, and stated that he thought the ZOSTAVAX might had been stored improperly since May 2013 and that the temperature of the ZOSTAVAX had ranged between 15F and 20F for an unspecified amount of hours. At that time the reporter was unsure if the ZOSTAVAX was administered but stated that he thought the ZOSTAVAX would had been administered. On further investigation, the pharmacist reported that ZOSTAVAX had been improperly stored since about 10-OCT-2013 reaching a highest of 20F for a total time of 600 hours. It was reported that the patient had no adverse effect. Further investigation stated that the pharmacist had determined that this case might involve approximately 5 different lots of ZOSTAVAX (details unspecified) stored improperly at temperatures up to 21F. He stated the time frame for the excursions would be as of the day each of the ZOSTAVAX lots was received at his facility through the date of patient administration, which he believed might had been months, dating back to an unknown date in May 2013. These involved approximately 40 patients. He had no specific breakdown of time frame as his records didn't indicate when he received each lot but he was calling further for the data. He also could not identify, at this time, which Lot# was administered on which date. Pharmacist would call back after he had compiled all of the necessary information and would like revaccination recommendations for any excursion that could not be supported. Pharmacist stated there had been no adverse effects noted by any of the patients. The pharmacist faxed a spreadsheet which included the 38 patients names, the date of administration as well as the lot and expiration dates of ZOSTAVAX which was unsupported an administrated. This is one of several reports from the same source. Additional information has been requested.
I lost my hearing and I have 30% left; I had the tinkering sound in my ear; This is a spontaneous report from a contactable consumer (patient). A 41-year-old female patient received bnt162b2 (Lot Number: EW0171), dose 2 via an unspecified route of administration on 05May2021 (at the age of 40 years old) as single dose for covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient previously received bnt162b2 (Lot Number: EW0161), dose 1 via an unspecified route of administration on 14Apr2021 (at the age of 40 years old) as single dose for covid-19 immunization. The patient took last dose (second dose) on 05May2021, one months later she lost her hearing and she had 30% left and she didn't have another reason she was very healthy women and she didn't have any family problem of hearing loss. She was very active and anyway when she wake up on 25Jun2021 she had the tinkering sound in her ear she went to the specialist of ear, nose and throat (ENT) Specialist, did examine the geometry and she lost her hearing and the hearing loss was because of the shot and she couldn't find any other reason. The patient underwent lab tests and procedures which included the patient had the blood test the shot on 11May2021, ENT examination stated as 'I lost her hearing' on 25Jun2021. The outcome of events was unknown.   Follow-up attempts are completed. No further information is expected.
2/6/23 patient scheduled bivalent booster, came in brought in one immunization card , counseled on bivalent vaccine and given vaccine. Next day 2/7/23 husband came in for vaccine but had 2 immunization cards and had bivalent vaccine listed on second card already. Called Patient 2/7/23 at home and reviewed vaccine record with patient and records and had already received bivalent at another location  9/21/22. Therefore Patient received 2 doses of the bivalent covid vaccine. She was not reporting any adverse effects at the time of the phone call
Chronic Sleepiness during the day! I feel like I just want to lay down and go to sleep while at work since the injection date. Lost all my energy.
The patient received a dose of the vaccine following temperature excursions on unknown dates; No adverse event; This spontaneous report as received from a medical assistant refers to a current 1-year-old patient of unknown gender.  The patient's concurrent conditions, medical history and concomitant medications were not provided.   On an unknown date, the vaccines hepatitis a vaccine, inactivated(VAQTA) (lot # S019435 with expiration date 23-AUG-2020, lot # S026003 with expiration date 17-OCT-2020, and lot # S032056 with expiration date 09-NOV-2020) underwent a temperature excursion.   Temperature Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) Time frame 7 hours 30 minutes Previous temperature excursion? yes, Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) for 8 hours 30 minutes Was call because of a "data logger"? yes  On an unknown date, the patient was vaccinated with hepatitis a vaccine, inactivated (VAQTA) 25/0.5 dosage form at a dose of 0.5 ml (route not provided) for prophylaxis. No adverse events were reported.  This is one of several cases from the same reporter.  combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. ; devicelotnumber: S019435; expirationdate: 23-AUG-2020; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not suggest a causal association with the device or device constituent; Sender's Comments:  US-009507513-2005USA003382: US-009507513-2005USA004521: US-009507513-2005USA004522: US-009507513-2005USA004523: 3US-009507513-2005USA004524: US-009507513-2005USA004525: US-009507513-2005USA004526: US-009507513-2005USA004527: US-009507513-2005USA004528: US-009507513-2005USA004529: US-009507513-2005USA004530: US-009507513-2005USA004532: US-009507513-2005USA004533: US-009507513-2005USA004534: US-009507513-2005USA004535: US-009507513-2005USA004536:
Headache fatigue, site pain Narrative:  Symptoms/complaints: Headache & Tiredness, increased soreness on arm.
BODY ACHES; DIZZINESS; FEVER; VERY TIRED FEELING; HEADACHE; This spontaneous report received from a patient concerned a 30 year old female. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 042A21A, and expiry: UNKNOWN) dose was not reported, administered on 03-APR-2021 on left arm for prophylactic vaccination. No concomitant medications were reported. On 03-APR-2021, the subject experienced body aches. On 03-APR-2021, the subject experienced dizziness. On 03-APR-2021, the subject experienced fever. On 03-APR-2021, the subject experienced very tired feeling. On 03-APR-2021, the subject experienced headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from fever on APR-2021, and had not recovered from body aches, very tired feeling, headache, and dizziness. This report was non-serious.
Momentarily dizzy then large itching, red and hot welt at injection site 6-7 inches long and 4 inches wide that increased over two days to 11 inches long and 6 inches wide with redness, heat and itching.
achey; headachy; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A female patient received bnt162b2 (BNT162B2), administration date 03May2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (first dose), for Covid-19 immunization. The following information was reported: PAIN (non-serious) with onset 04May2021, outcome "unknown", described as "achey"; HEADACHE (non-serious) with onset 04May2021, outcome "unknown", described as "headachy".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient received a booster dose (unknown primary series) that was one day past the 31-day use-by timeframe as indicated on Pfizer packaging.   The following day I contacted Pfizer and learned that according to their own research the vaccine is equally viable 32 days after thaw.  No adverse signs or symptoms reported by the patient.
Patient may have received two Prevnar#1 and no Vaxlelis #1 during their 2 months appointment. No adverse outcome reported by mother at home. Checked in 1 month post vaccination, baby still doing well.
Vaccine at 0935 Immediate Metal taste noted by employee (did not report to EH) 10 Minutes later then noted tongue and teeth numb with continued metal taste 1015 took 25 mg Benadryl - sx continue.
Pt vaccinated with FLU: developed lft sore arm 2 days following immun.; had nausea for 2 days follwing flu shot; intermittent sharp pains in lft temple began 11/30 kept patient awake and lasted until 12/3/90. Consulted w/ PMD  by telephone.
arm was sore; arm with a lump; immune system went in full alert; achy joints; This case was reported by a consumer via interactive digital media and described the occurrence of pain in arm in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced pain in arm, local swelling, immune system disorder and joint pain. On an unknown date, the outcome of the pain in arm, local swelling, immune system disorder and joint pain were recovered/resolved.   It was unknown if the reporter considered the pain in arm, local swelling, immune system disorder and joint pain to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 04-JUN-2022 Reporter's Comment: This case was reported by a patient via interactive digital media. The patient's arm was sore with a lump for a couple of days and the day after the shot, his/her immune system went in full alert, so achy joints for a day, but that was it. Additional Supportive Information: The follow up would not possible, as no contact details were available.
Pt had rash around inj site and around neck. Redness. Swelling and pt complaint of itching. Redness has subsided when I examined her.
Information has been received from a nurse, concerning a 62 year old male patient who on 19-OCT-2007 was vaccinated with a dose, 0.5 ml, of Pneumovax 23 (lot #655765/0061U). There was no concomitant medication. Following the vaccination, the patient became lightheaded, had a headache, had severe muscle weakness, developed a fever of 100 degrees and was "so sore he could not even walk up the steps." The following day, 20-OCT-2007, the patient recovered. The patient sought unspecified medical attention. The reporting nurse considered the events to be clinically significant disabling/incapacitating. Additional information has been requested.
Approx 2 minutes after getting the vaccine, patient complained of her throat feeling tight, but she was not having difficulty breathing. Patient was given 25mg of oral BENADRYL and monitored. Pt's BP 126/62 HR 71, patient stable and responsive with no difficutly breating, but she started to complain about headache and feeling nausea and dizziness. Since patient was not improving after 15 minutes 911 was notified. Patient was examined and cleared as non emergency, and gave patient option to either be taken by ambulance or to go to her doctor instead. Patient opted to be taken to the ER by ambulance.
Pt fainted immediately post flu vaccine administration, was only unconscious for a few seconds- approx 30 sec. , - immunizing certified technician immediately braced pt's slump forward in chair.  Pt did not report any other adverse reactions.  Pt was instructed to sit in immunization room for at least 5 minutes. - reported ok - her mother was with her & they were instructed to wait in waiting area for a few more mins.  Later in afternoon, Mom called & reported that patient was again feeling very dizzy, nauseous, and her hands were tingly.  Mom was instructed to monitor & if there was any increased adverse reactions including difficulty breathing to call 911.   Checked on patient the next day & she reported no residual issues... feeling just fine.
July 15 I started bleeding; July 19 - when the miscarriage happened. Pregnancy - 1 live birth pregnancy - 2nd miscarriage.  - (three pregnancies altogether). Estimated due date - February 2nd, 2022
Client's mother contacted clinic on Friday 10/05/2018 stating that patient didn't go to school today because she has been having following symptoms since received TDaP vaccine yesterday: 15 minutes after getting her vaccine, in the car she started having tingling, numbness in her left arm, cramps and tingling in both legs, back and neck pain. When asked about her immunizations previously, mother stated that she had her first vaccines at age 3 and was given only 1 vaccine at a time and didn't have any reactions or side effects and her vaccines were spaced. On day of vaccination client was advised to wait in waiting room for 15 minutes per our policy, she was not complaining of any problems right after receiving TDaP vaccine and stated that she expected to have more pain. Mother was instructed to contact PMD regarding this problem, or go to local ER if client's condition worsens, and also let our clinic know how her daughter is doing. On October 9th mother was contacted to f/u on her daughter's condition and she stated that patient was feeling better and went to school today.
Soreness and disabled triceps muscle (two days), no treatment, gradually became usable again; fever with migraine and sore throat (second day), treated with ibuprofen, normal on third day
Felt seek; Diverticulitis exacerbation; Recommendations to defer the second vaccination from Physician; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 25-May-2021 and was forwarded to Moderna on 25-May-2021.    This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of DIVERTICULITIS (Diverticulitis exacerbation) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 018B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included METFORMIN, ROSUVASTATIN, ATENOLOL, LANSOPRAZOLE (PREVACID), ALPRAZOLAM (XANAX), VENLAFAXINE HYDROCHLORIDE (EFFEXOR) and DICYCLOMINE [DICYCLOVERINE] for an unknown indication.    On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, the patient experienced OFF LABEL USE (Recommendations to defer the second vaccination from Physician). On 17-Apr-2021, the patient experienced DIVERTICULITIS (Diverticulitis exacerbation) (seriousness criterion medically significant). On 25-May-2021, the patient experienced MALAISE (Felt seek). At the time of the report, DIVERTICULITIS (Diverticulitis exacerbation) and MALAISE (Felt seek) had not resolved and OFF LABEL USE (Recommendations to defer the second vaccination from Physician) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       It was reported that the patient was not hospitalized and had no surgery but received recommendations to defer the second vaccination from Physician. For now patient still had exacerbation and "felt seek" so asked to defer second vaccination presumably on 05Jun2021 which is out of recommended time frame. No treatment information was provided.  Company Comment : Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Right thigh with redness and swelling, emesis, fever up to 102; increase BM x 3 in one hour, otitis
Has not been able to get the second dose yet; A spontaneous report was received from a consumer concerning a 73 years old female patient, who has not been able to get the second dose yet (Inappropriate schedule of product administration).  The patients medical history was not provided. Concomitant product use was not provided by the reporter.  On 01 Feb 2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA for prophylaxis of COVID-19 infection.  It was reported that the patient has not been able to get the second dose of vaccine yet. The reason was not provided.  Treatment information was unknown.   Action taken with mRNA-1273 in response to the events was not reported.   The event, not been able to get the second dose yet (Inappropriate schedule of product administration) was considered as unknown.; Sender's Comments: This report refers to a case of Inappropriate Schedule Of Product Administration for mRNA-1273 (Lot #: Unknown) with no associated AEs.
6 x 4 red, swollen welt at injection site.; 6 x 4 red, swollen welt at injection site.; 6 x 4 red, swollen welt at injection site.; Temp at injection site is 101.8 degrees; Swollen lymph node in left armpit, size of softball; Dose received:3; This is a spontaneous report from a contactable reporter (consumer or other non-HCP). The reporter is the patient.  A 40 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 21Dec2021 at 09:00 (Lot number: 3313OBA) at the age of 40 years as dose 3 (booster), single for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, Lot number: EP6955, Anatomical location: left arm, Route of administration: Unspecified), administration date: 24Mar2021, when the patient was 40 years old, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE, Lot number: EW015, Anatomical location: left arm, Route of administration: Unspecified), administration date: 14Apr2021, when the patient was 40 years old, for COVID-19 immunisation.  The following information was reported: IMMUNISATION (non-serious) with onset 21Dec2021 at 09:00, outcome "unknown", described as "Dose received:3"; VACCINATION SITE ERYTHEMA (non-serious), VACCINATION SITE SWELLING (non-serious), VACCINATION SITE URTICARIA (non-serious), VACCINATION SITE WARMTH (non-serious), LYMPHADENOPATHY (non-serious) all with onset 23Dec2021 at 03:00, outcome "not recovered", and all described as "6 x 4 red, swollen welt at injection site". The events "6 x 4 red, swollen welt at injection site.", "Temp at injection site is 101.8 degrees" and "Swollen lymph node in left armpit, size of softball" were evaluated at the physician office visit. It was unknown whether any therapeutic measures were taken as a result of the events. Relevant laboratory tests and procedures are available in the appropriate section. Additional Information: The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to COVID-19 vaccine. Temperature at injection site was 101.8 degrees and swollen lymph node in left armpit which was in the size of softball. Since the vaccination, the patient had not been tested for COVID-19.
Narrative: Patient experienced symptoms of fever, muscle pain, and chills after both doses of the COVID-19 vaccine.
Warm, erythematous, indurated, non fluctuating  skin lesion on lateral deltoid.
This spontaneous report as received from a physician refers to a patient of unknown age. On an unknown date the patient was vaccinated with M-M-R II lot # L020189 for prophylaxis. Concomitant therapies included sterile diluent(STERILE DILUENT). On 08-JUN-2017 the patient experienced expired product administered. On an unknown date the patient experienced no adverse event. The outcome of expired product administered and no adverse event is unknown. The reporter considered expired product administered and no adverse event to be not related to M-M-R II. Additional information has been requested.